Trial Profile

Phase IIb/III Randomized, Double-blind Trial of BIBW 2992 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-Lung 1)

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 06 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Afatinib (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms LUX-Lung-1
Sponsors Boehringer Ingelheim Pharmaceuticals

Most Recent Events

07 Jul 2011 Quality-of-life and symptom analysis presented at the 14th World Conference on Lung Cancer.
11 Feb 2011 New source identified and integrated (United Kingdom Clinical Research Network record 9861).
09 Dec 2010 Results of a subgroup analysis in patients most likely to have EGFR mutations (n=385), presented at the Chicago Multidisciplinary Symposium in Thoracic oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com